• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunome Inc (NQ: IMNM )

    15.04 +0.22 (+1.48%)
    Streaming Delayed Price Updated: 12:31 PM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 163,154
    Open 14.61
    Bid (Size) 14.99 (3)
    Ask (Size) 15.05 (5)
    Prev. Close 14.82
    Today's Range 14.56 - 15.20
    52wk Range 6.130 - 30.96
    Shares Outstanding 59,968,868
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Immunome Appoints Phil Tsai as Chief Technical Officer
    From Immunome, Inc.
    Via Business Wire
    Evaluating Immunome: Insights From 4 Financial Analysts
    Via Benzinga

    Performance

    YTD
    +36.60%
    +36.60%
    1 Month
    +25.96%
    +25.96%
    3 Month
    +2.59%
    +2.59%
    6 Month
    +0.33%
    +0.33%
    1 Year
    +106.88%
    +106.88%

    More News

    Read More
    Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Immunome Announces Completion of Purchase of Assets from Atreca
    From Immunome, Inc.
    Via Business Wire
    Immunome Announces Promotion of Max Rosett to Chief Financial Officer
    From Immunome, Inc.
    Via Business Wire
    IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
    From Immunome, Inc.
    Via Business Wire
    Immunome to Present at 2024 Bank of America Healthcare Conference
    From Immunome, Inc.
    Via Business Wire
    Immunome Appoints Kinney Horn as Chief Business Officer
    From Immunome, Inc.
    Via Business Wire
    Immunome Appoints Sandra M. Swain to Board of Directors
    From Immunome
    Via Business Wire
    Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
    From Immunome, Inc.
    Via Business Wire
    IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
    From Immunome, Inc.
    Via Business Wire
    Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?
    Via Benzinga
    Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
    From Immunome, Inc.
    Via Business Wire
    Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Immunome to Participate in the Leerink Partners Global Biopharma Conference
    From Immunome, Inc.
    Via Business Wire
    Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
    From Immunome, Inc.
    Via Business Wire
    Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?
    Via Benzinga
    How I Swing Trade Via Strength With Recent Examples
    Via Talk Markets
    Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
    From Immunome, Inc.
    Via Business Wire
    Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
    From Ayala Pharmaceuticals
    Via GlobeNewswire
    Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Immunome, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.